Oral berberine alone or combined with letrozole,
does it really help with Cumulative live birth in infertility associated with PCOS?
research showsGrade D with 34 points. In a 644-person multicenter double-blind trial, cumulative live birth was 36% with letrozole, 34% with the combination, and 22% with berberine alone. Berberine did not improve live birth when added to letrozole, and the monotherapy arm was lower.
ads claimIt cannot be advertised as a natural ovulation inducer, a letrozole replacement, or a way to raise live-birth rates when combined.
Useful facts when choosing a product
- This verdict applies only to the displayed formulation, route, dose, duration, population, endpoint, and comparator.
- Berberine hydrochloride, botanical extracts, combination formulas, dihydroberberine, other derivatives, and topical products are not interchangeable.
- Warning. Self-administration cannot be recommended while trying to conceive; if pregnancy occurs, promptly review use with a clinician because of fetal/neonatal bilirubin concerns.
Chamgap Semantic Classification Code
Permanent code issued
S.berberine.oral.cumulative-live-birth.increase.letrozoleSupplements and nutraceuticals > Berberine (exact salt form unverified) > Oral > PCOS cumulative live birth > Increase claim > Letrozole alone and combination
Issued only for cumulative live birth; ovulation, pregnancy rate, and metabolic markers are separate. The correct registry is ChiCTR-TRC-09000376. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Berberine |
| Source or part used | Exact salt form and source plant unverified |
| Formulation or processing | Double-dummy berberine/placebo and letrozole/placebo tablets; exact salt form unverified |
| Route | Oral |
| Dose | Berberine 1.5 g/day; letrozole 2.5 mg on cycle days 3-7, increasing to 5 mg if needed |
| Duration | Up to six months with pregnancy-outcome follow-up |
| Population | 644 infertile women meeting Rotterdam PCOS criteria |
| Effect or condition | Higher cumulative live birth |
| Primary endpoint | Cumulative live birth during treatment |
| Comparator | Letrozole alone and letrozole plus berberine |
| Duplicate-detection key | Berberine|Double-dummy berberine/placebo and letrozole/placebo tablets; exact salt form unverified|Oral|644 infertile women meeting Rotterdam PCOS criteria|Higher cumulative live birth|Up to six months with pregnancy-outcome follow-up |
What the research actually shows
The paper was matched to the WHO/ChiCTR record, and a wrongly associated NCT number was excluded.
Why this is classified as D (34)
Axes are H/R1/I2/E-/B0/C1 with big_hard_rct. Five strengths are present, but under the E- rule without RX the result is D/34.
Counterpoint. Possible metabolic effects are a separate question and cannot replace the direct null/inferior live-birth result.
Rejudgment record. Independent Codex cross-check — One formulation, route, population, claim, principal endpoint, and comparator
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E- | Harm increased in the trials |
| Precision | C1 | The confidence interval excludes meaningful benefit |
The scoring table and the verdict agree (D).
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Randomized controlled trial of letrozole, berberine, or a combination for infertility in the polycystic ovary syndrome | Design, allocation, masking, endpoint hierarchy, and analysis set were independently checked. | 1 | Funding, product support, employee authorship, and conflicts were assessed separately. | The principal endpoint contract is preserved; other outcomes remain separate. | Verified estimates are preserved; missing confidence intervals were not invented. | Evidence weight reflects directness, formulation match, hierarchy, and reporting limitations. |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-09-08).
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Cite this verdict
[Chamgap] Berberine for PCOS Live Birth—22% Alone Versus 36% With Letrozole, With No Added Combination Benefit — Evidence Grade D·34. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/womens/berberine-pcos-cumulative-live-birth/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.